GlassScriptPhysician profile
Eric A Harlan
NPI 1487809190
$1,217.01
in general payments reported to CMS, 2019-2025
20 companies · $88.46 in 2025
The $88.46 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $121 · 2021: $81.61 · 2022: $194 · 2023: $151 · 2024: $293 · 2025: $88.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.18 |
| Education | $135.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $232.07 | 2019-2024 | Tremfya |
| Galderma Laboratories, L.P. | $117.96 | 2019-2024 | Aklief |
| Dusa Pharmaceuticals, INC. | $112.50 | 2019 | |
| Abbvie INC. | $106.92 | 2019-2024 | |
| Pfizer INC. | $105.86 | 2022-2024 | |
| Lilly USA, LLC | $77.68 | 2020-2024 | Taltz, Ebglyss, Olumiant |
| Prugen, INC. Pharmaceuticals | $73.43 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.27 | 2019-2024 | Jublia, Arazlo, Duobrii |
| Novartis Pharmaceuticals Corporation | $54.10 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $46.47 | 2020-2025 | |
| Dermavant Sciences, INC. | $41.38 | 2023-2024 | Vtama |
| Organon LLC | $33.59 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $32.99 | 2023-2024 | Zoryve |
| Genzyme Corporation | $27.40 | 2022 | |
| Celgene Corporation | $18.84 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $17.78 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.45 | 2020 | |
| Ucb, INC. | $15.71 | 2020 | |
| Incyte Corporation | $14.32 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Harlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.